
Zafir20 mg
ACME Laboratories Ltd.
Zafirlukast is a leukotriene receptor antagonist (LTRA) indicated for the prophylaxis and chronic maintenance treatment of asthma in adults and children.
Zafirlukast is a leukotriene receptor antagonist (LTRA) indicated for the prophylaxis and chronic maintenance treatment of asthma in adults and children.
Zafirlukast is not indicated for reversal of acute bronchospasm, including status asthmaticus. It is not a rescue medication; patients must have a separate fast-acting bronchodilator available at all times for acute asthma symptoms.
Dosage of Zafirlukast should be individualized based on age, and treatment should continue even during symptom-free periods as part of chronic maintenance therapy.
| Population | Recommended Dose |
|---|---|
| Adults and children 12 years and older | 20 mg orally twice daily |
| Children 5 to 11 years | 10 mg orally twice daily |
| Elderly patients | Standard adult dose; clearance may be reduced 2- to 3-fold, so clinical monitoring is advised |
Zafirlukast should be taken at least 1 hour before or 2 hours after meals, as food significantly reduces its absorption.
Common side effects of Zafirlukast include:
Serious but rare risks — including hepatotoxicity, neuropsychiatric events, and Churg-Strauss syndrome — are discussed in detail under Precautions and Warnings; seek medical attention promptly if these occur.
Zafirlukast is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.